As of June 30, 2024, cash and cash equivalents were $300.1 million, compared to $278.6 million as of December 31, 2023. In May 2024 the Company completed an underwritten offering resulting in net proceeds of approximately $97.4 million, extending the expected cash runway into mid-2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADCT:
- ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
- ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
- ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
- ADC Therapeutics rises 16.5%
- ADC Therapeutics rises 10.1%